Kumar Palaniappan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kumar Palaniappan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Rela
The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India
5 shared publications - Ashwin Rammohan
The Institute of Liver Disease & Transplantation, Dr.Rela Institute & Medical Centre, Bharath Institute of Higher Education & Research, Chennai, India
4 shared publications - Rajesh Rajalingam
Department of HPB Surgery and Liver Transplantation, Institute of Liver Diseases and Transplantation, Dr. Rela Institute and Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India
4 shared publications - Sadhana Shankar
Institute of Liver Disease and Transplantation, Dr. Rela Institute Medical Centre, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India
3 shared publications - Gomathy Narasimhan
Department of Renal and Liver Transplant Surgery, Dr. Rela Institute and Medical Centre, Bharat Institute of Higher Education and Research, Chennai, India
2 shared publications - Mukul Vij
Institute of Liver Disease & Transplantation, Dr Rela Institute & Medical centre, Bharath Institute of Higher Education and Research, Chennai, India
2 shared publications
Latest Publications
- 30 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Reappraising Liver Transplantation for Combined Hepatocellular-cholangiocarcinoma
Objective: To determine whether liver transplantation (LT) confers durable oncologic benefit in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to identify predictors of recurrence that may guide transplant candidacy. Background: cHCC-CCA is a rare primary liver malignancy with aggressive biological behavior. LT has traditionally been contraindicated due to concerns regarding recurrence. We evaluated long-term outcomes of LT versus liver resection (LR) and compared LT outcomes for cHCC-CCA with those for hepatocellular carcinoma (HCC). Methods: Patients with cHCC-CCA who underwent LT or LR between 2010 and 2024 were identified from a prospective database. Survival outcomes, recurrence patterns, and risk factors for recurrence were analyzed. Outcomes of LT for cHCC-CCA were additionally compared with HCC. Results: A total of 79 patients underwent LT (diagnosed on explant) and 32 underwent LR for cHCC-CCA. 5-year overall survival (OS) and recurrence-free survival (RFS) were superior following LT compared with LR (OS: 89.9% vs. 65.6%, P =0.007; RFS: 84.8% vs. 53.1%, P =0.001). This benefit was maintained for tumors within UCSF criteria [overall survival (88.7% LT vs. 65.6% LR, log rank P 0.014) and RFS (89.8% LT vs. 51.6% LR, P P =0.721). Within the LT cohort, macrovascular invasion (HR 25.01, P =0.003) and poor tumor differentiation (HR 7.29, P =0.004) independently predicted recurrence. Conclusion: In carefully selected patients, cHCC-CCA within UCSF criteria can achieve transplant outcomes comparable to HCC. Macrovascular invasion and poor tumor differentiation are major predictors of recurrence and may inform candidate selection for LT.
- 30 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Reappraising Liver Transplantation for Combined Hepatocellular-cholangiocarcinoma
Objective: To determine whether liver transplantation (LT) confers durable oncologic benefit in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to identify predictors of recurrence that may guide transplant candidacy. Background: cHCC-CCA is a rare primary liver malignancy with aggressive biological behavior. LT has traditionally been contraindicated due to concerns regarding recurrence. We evaluated long-term outcomes of LT versus liver resection (LR) and compared LT outcomes for cHCC-CCA with those for hepatocellular carcinoma (HCC). Methods: Patients with cHCC-CCA who underwent LT or LR between 2010 and 2024 were identified from a prospective database. Survival outcomes, recurrence patterns, and risk factors for recurrence were analyzed. Outcomes of LT for cHCC-CCA were additionally compared with HCC. Results: A total of 79 patients underwent LT (diagnosed on explant) and 32 underwent LR for cHCC-CCA. 5-year overall survival (OS) and recurrence-free survival (RFS) were superior following LT compared with LR (OS: 89.9% vs. 65.6%, P =0.007; RFS: 84.8% vs. 53.1%, P =0.001). This benefit was maintained for tumors within UCSF criteria [overall survival (88.7% LT vs. 65.6% LR, log rank P 0.014) and RFS (89.8% LT vs. 51.6% LR, P P =0.721). Within the LT cohort, macrovascular invasion (HR 25.01, P =0.003) and poor tumor differentiation (HR 7.29, P =0.004) independently predicted recurrence. Conclusion: In carefully selected patients, cHCC-CCA within UCSF criteria can achieve transplant outcomes comparable to HCC. Macrovascular invasion and poor tumor differentiation are major predictors of recurrence and may inform candidate selection for LT.
- Open Access
- 9 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 164-169
Effect of donor warm ischemia time during graft extraction in right lobe robotic donor hepatectomy on recipient outcomes—A propensity score matched analysis
- 9 July 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (1) , 164-169
Open AccessEffect of donor warm ischemia time during graft extraction in right lobe robotic donor hepatectomy on recipient outcomes—A propensity score matched analysis
- Open Access
- 9 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (6) , 786-793
Anatomical variations of left hepatic vein and outflow reconstruction techniques in pediatric living donor liver transplantation
- 9 March 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (6) , 786-793
Open AccessAnatomical variations of left hepatic vein and outflow reconstruction techniques in pediatric living donor liver transplantation
- 17 April 2021
- Published by Wiley in World Journal of Surgery
- Vol. 45 (8) , 2567-2571
Renal Implications of Left Renal Vein Ligation for Portal Flow Augmentation in Liver Transplantation
Background: Spontaneous lienorenal shunts (SLS) siphon blood away from the portal circulation and may compromise portal inflow in liver transplantation (LT). Performing a left renal vein ligation (LRVL) is a relatively easy and efficacious method of overcoming this portal ‘steal’. However, given the delicate state of renal function in these patients, its short and long term effects remain undefined. The aim of this study was to evaluate the efficacy of LRVL in augmenting portal flow and safety with regards to renal function.Methods: A prospectively collected database of 1638 consecutive LT recipients between January 2010 and August 2020 was reviewed. Twenty‐eight patients who underwent LRVL were identified. There were six paediatric recipients, who were analysed separately. Data with regards to imaging, renal function, intraoperative portal hemodynamics, and renal morbidity were analysed.Results: Of the 22 adults, 21 underwent live donor LT. 22.5% had a pre‐transplant history of acute kidney injury (AKI). Pre‐operative CT demonstrated portal vein thrombosis and SLS in 63.6% and 92.9% of patients respectively. LRVL resulted in a significant augmentation of portal hemodynamics in both the adult and paediatric recipients. Postoperatively, 14.3% and 35.7% of patients developed chylous drain output and AKI respectively. Of 13 patients who underwent CT at various timeframes, 5 patients had a partial re‐canalisation of LRV at 6 months.Conclusion: From renal and portal standpoints, LRVL is a safe and effective technique of augmenting portal inflow. Further large‐scale multicentre studies and consensus will help define an objective algorithmic approach to LT recipients with SLS.
- 17 April 2021
- Published by Wiley in World Journal of Surgery
- Vol. 45 (8) , 2567-2571
Renal Implications of Left Renal Vein Ligation for Portal Flow Augmentation in Liver Transplantation
Background: Spontaneous lienorenal shunts (SLS) siphon blood away from the portal circulation and may compromise portal inflow in liver transplantation (LT). Performing a left renal vein ligation (LRVL) is a relatively easy and efficacious method of overcoming this portal ‘steal’. However, given the delicate state of renal function in these patients, its short and long term effects remain undefined. The aim of this study was to evaluate the efficacy of LRVL in augmenting portal flow and safety with regards to renal function.Methods: A prospectively collected database of 1638 consecutive LT recipients between January 2010 and August 2020 was reviewed. Twenty‐eight patients who underwent LRVL were identified. There were six paediatric recipients, who were analysed separately. Data with regards to imaging, renal function, intraoperative portal hemodynamics, and renal morbidity were analysed.Results: Of the 22 adults, 21 underwent live donor LT. 22.5% had a pre‐transplant history of acute kidney injury (AKI). Pre‐operative CT demonstrated portal vein thrombosis and SLS in 63.6% and 92.9% of patients respectively. LRVL resulted in a significant augmentation of portal hemodynamics in both the adult and paediatric recipients. Postoperatively, 14.3% and 35.7% of patients developed chylous drain output and AKI respectively. Of 13 patients who underwent CT at various timeframes, 5 patients had a partial re‐canalisation of LRV at 6 months.Conclusion: From renal and portal standpoints, LRVL is a safe and effective technique of augmenting portal inflow. Further large‐scale multicentre studies and consensus will help define an objective algorithmic approach to LT recipients with SLS.
- 22 March 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (3) , 1165-1168
Recurrent Intestinal Perforation After Cessation of Immunosuppression in Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Recipient
Posttransplant lymphoproliferative disease (PTLD) is the most common malignant complication after solid organ transplantation. Gastrointestinal involvement as the presentation in early PTLD can occur in 25–30% of pediatric liver transplant recipients and can be the only system involved in 20%. Recurrent gastrointestinal perforation due to resolution of PTLD is an extremely rare complication. We report a 13-month-old male child diagnosed with PTLD, treatment of which lead to recurrent intestinal perforations. The child presented with gastrointestinal bleed 5 months after living donor liver transplantation for biliary atresia. Evaluation was suggestive of PTLD and biopsy confirmed diffuse large B-cell lymphoma. Positron emission tomography scan showed diffuse involvement of small intestine and ileum. Tacrolimus was withdrawn abruptly following diagnosis of PTLD as there was associated renal impairment. Child developed six episodes of small intestinal perforations over 3 weeks which required multiple laparotomies with closure of perforation and/or small bowel resection. Complete remission was achieved six months after diagnosis with cessation of immunosuppression alone and child is alive at 48 months follow-up without any recurrence. To avoid bowel perforation and complications related to tumor necrosis, immunosuppression reduction in PTLD should be gradual while carefully monitoring Epstein–Barr virus levels, tumor response, graft function, and general health status of the patient.
- 22 March 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (3) , 1165-1168
Recurrent Intestinal Perforation After Cessation of Immunosuppression in Posttransplant Lymphoproliferative Disease in Pediatric Liver Transplant Recipient
Posttransplant lymphoproliferative disease (PTLD) is the most common malignant complication after solid organ transplantation. Gastrointestinal involvement as the presentation in early PTLD can occur in 25–30% of pediatric liver transplant recipients and can be the only system involved in 20%. Recurrent gastrointestinal perforation due to resolution of PTLD is an extremely rare complication. We report a 13-month-old male child diagnosed with PTLD, treatment of which lead to recurrent intestinal perforations. The child presented with gastrointestinal bleed 5 months after living donor liver transplantation for biliary atresia. Evaluation was suggestive of PTLD and biopsy confirmed diffuse large B-cell lymphoma. Positron emission tomography scan showed diffuse involvement of small intestine and ileum. Tacrolimus was withdrawn abruptly following diagnosis of PTLD as there was associated renal impairment. Child developed six episodes of small intestinal perforations over 3 weeks which required multiple laparotomies with closure of perforation and/or small bowel resection. Complete remission was achieved six months after diagnosis with cessation of immunosuppression alone and child is alive at 48 months follow-up without any recurrence. To avoid bowel perforation and complications related to tumor necrosis, immunosuppression reduction in PTLD should be gradual while carefully monitoring Epstein–Barr virus levels, tumor response, graft function, and general health status of the patient.